Results 11 to 20 of about 174,614 (242)

Degradation rate of 5-fluorouracil in metastatic colorectal cancer. A new predictive outcome biomarker? [PDF]

, 2016
BACKGROUND: 5-FU based chemotherapy is the most common first line regimen used for metastatic colorectal cancer (mCRC). Identification of predictive markers of response to chemotherapy is a challenging approach for drug selection.
Borro, Marina, Botticelli, Andrea, Cerbelli, Bruna, Gentile, Giovanna, Lionetto, Luana, Marchetti, Luca, Marchetti, Paolo, Mazzuca, Federica, Occhipinti, Mario, Onesti, CONCETTA ELISA, Romiti, Adriana, Sebastiani, Claudia, Simmaco, Maurizio, Strigari, Lidia   +13 more
core   +15 more sources

5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine [PDF]

, 2020
Capecitabine is an oral prodrug of 5-fluorouracil with a relevant role in the treatment of breast cancer. Severe and unexpected toxicities related to capecitabine are not rare, and the identification of biomarkers is challenging.
Botticelli, A., Cerbelli, B., Lionetto, L., Marchetti, P., Roberto, M., Scagnoli, S., Simmaco, M.   +6 more
core   +1 more source

Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia [PDF]

, 2007
Background: Irinotecan-based second-line chemotherapy of metastatic colorectal cancer (CRC) is effective, it might, however, be contraindicated in cases of severe liver dysfunction due to advanced liver metastases.
Heinemann, Volker, Laessig, Dorit, Michaely, Henrik Jakob, Moosmann, Nicolas, Schulz, Christoph   +4 more
core   +1 more source

Green synthesis and biological evaluation of novel 5-fluorouracil derivatives as potent anticancer agents [PDF]

, 2019
This study reports the formation of 5-FU co-crystals with four different pharmacologically safe co-formers; Urea, Thiourea, Acetanilide and Aspirin using methanol as a solvent. Two fabrication schemes were followed i.e., solid-state grinding protocol, in
Abdelghani, Ahmed, Aisha Liaqat, Ansari, Baumgartner, Carrillo, Dai, Delori, Dong, Douroumis, Fang, Fang, Farhat Jubeen, Farooq Sher, Imran Sajid, Jubeen, Karimi-Jafari, Köksal Karayildirim, Langley, Li, Li, Likhitha, Misbah Sultan, Miura, Mohana, Moisescu-Goia, Moku, Nadzri, Ofonime Udofot, Patel, Petaccia, Qin, Qin, Qin, Radwan, Rakesh, Rakesh, Reinsch, Sania Zafar Iqbal, Shakeel, Sonawane, Stoler, Subudhi, Suthindhiran, Vichai, Wang, Yan, Zha, Zha, Zhang, Zhang, Zhao, Zhao, Zhou   +53 more
core   +2 more sources

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. [PDF]

, 2017
BackgroundTopoisomerase I (TOPO1) and topoisomerase IIα (TOP2A) are specific targets of multiple chemotherapy drugs. Increased expression of TOPO1 protein and amplification of the TOP2A gene have been associated with treatment response in colorectal and ...
Arguello, David, Gatalica, Zoran, Heestand, Gregory M, Kurzrock, Razelle, Schwaederle, Maria   +4 more
core   +1 more source

Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer [PDF]

, 2012
Background: Data from meta-analyses have shown taxane-containing therapies to be superior to anthracycline-based treatments for high-risk breast cancer. Patients and Methods: The ADEBAR trial was a multicenter phase Ill trial in which patients with lymph
Aivazova-Fuchs, Viktoria, Andergassen, Ulrich, Annecke, Katja, Augustin, Doris, Friese, Klaus, Harbeck, Nadia, Hepp, Philip, Janni, Wolfgang, Jückstock, Julia K., Kiechle, Marion, Mohrmann, Svjetlana, Rack, Brigitte, Salmen, Jessica, Schönherr, Alexandra, Simon, Wolfgang, Wischnik, Arthur, Zwingers, Thomas   +16 more
core   +1 more source

Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure [PDF]

, 2002
Background: The cytotoxic treatment of patients suffering from advanced or metastatic cancer undergoing hemodialysis due to chronic renal failure still remains a problem, since for those patients pharmacokinetic and pharmacodynamic data on most cytotoxic
Hacker, U., Heinemann, Volker, Schalhorn, A., Stemmler, J., Weise, A.   +4 more
core   +1 more source

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. [PDF]

, 2018
BackgroundThe value of induction chemotherapy (ICT) remains under investigation despite decades of research. New advancements in the field, specifically regarding the induction regimen of choice, have reignited interest in this approach for patients with
Cohen, EEW, Haddad, RI, Hitt, R, Lefebvre, J-L, Posner, M, Schulten, J, Vermorken, JB   +6 more
core   +1 more source

Gemcitabine: Progress in the treatment of pancreatic cancer [PDF]

, 2001
Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor.
Heinemann, Volker
core   +1 more source

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC) [PDF]

, 2013
Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor
BASSO, ENRICO, CARUSO, DAVIDE, EVANGELISTA, SALVATORE, Foteini Vakiarou, G. Rinaldi, L. Bianchi, Lo Russo, Giuseppe, PAPA, ANSELMO, Perrone-congedi, Francesca, PRETE, ALESSANDRA ANNA, ROSSI, Luigi, SPINELLI, GIAN PAOLO, Stati, Valeria, TOMAO, SILVERIO, VERRICO, MONICA, ZORATTO, federica   +15 more
core   +1 more source